Zanubrutinib Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 80mg, 160mg
Reference Brands: Brukinsa (USA/EU)
Category:
Oncology Cancer Care
Zanubrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling, thereby reducing the growth and survival of malignant B cells. It is approved for the treatment of mantle cell lymphoma, CLL/SLL, and Waldenström’s macroglobulinemia. Zanubrutinib offers high selectivity with fewer off-target effects compared to earlier BTK inhibitors.
Zanubrutinib is available in Capsules
and strengths such as 80mg, 160mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Zanubrutinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Zanubrutinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing